4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $32.7143.

A number of research firms recently issued reports on FDMT. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Royal Bank Of Canada upped their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Finally, Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently bought and sold shares of the company. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth $41,000. Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after acquiring an additional 6,186 shares during the period. Abich Financial Wealth Management LLC purchased a new position in 4D Molecular Therapeutics during the third quarter worth about $80,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in 4D Molecular Therapeutics during the fourth quarter worth about $77,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $10.18 on Friday. The firm’s fifty day simple moving average is $8.89 and its 200-day simple moving average is $9.18. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $12.34. The stock has a market capitalization of $519.69 million, a price-to-earnings ratio of -4.21 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. The firm had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. Analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.